Early Detection of Neurofibromatosis Type-1 Brain Tumor Growth and Treatment Response by Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, and Positron Emission Tomography in a Trial of Novem Antitumor Drugs.
Annual rept. 22 Sep 93-21 Sep 96,
CHILDREN'S HOSPITAL OF PHILADELPHIA PA
Pagination or Media Count:
Standard evaluations of NF- 1 tumor and treatment response are inadequate and current therapies are ineffective. We conducted studies using MRI, MRS, and PET in 28 NF-1 patients with newly-diagnosed brain tumors and 7 with progressive tumors. Preliminary results show MRS and PET profiles similar to non-NF1 tumors. Predictive factors have not been identified. However, thalamic hypometabolism and hypoperfusion is significant in these patients. Neuroimaging data requires re-analysis in 9 months after all scheduled studies are completed. To address these problems, we conducted multimodality neuroimaging studies in NF-1 patients with newly-diagnosed or progressive optic nervehypothalamic or brain stem tumors to predict the growth potential of these tumor and a randomized clinical trial of new antitumor agents in progressively enlarging OPTHT and plexiform neurofibromas to rapidly identify potentially effective therapies.
- Medicine and Medical Research
- Atomic and Molecular Physics and Spectroscopy
- Nuclear Physics and Elementary Particle Physics